RECAF BLOOD TEST DETECTS 92% OF CERVICAL CANCERS.

BioCurex, Inc. (Pink Sheets:BOCX), Richmond, B.C., Canada, has completed a study in which its RECAF blood test detected 92% of cervical cancers using a drop of blood. The specificity of the test was 95.7%. The study included 25 cervical cancer blood samples and 69 normal blood samples. Currently, there is no commercial blood test available for the detection of cervical cancer.

The National Cancer Institute reports a sensitivity of 55-88% for detecting high-grade lesions using a traditional Pap test. (Certain changes in the diagnostic criteria -- combinations of reference thresholds -- may increase the Pap sensitivity to 70-80% with 95% specificity).

The 2005 estimated market size for Pap smears is $1 billion for 2005 (See Note). The diagnosis is performed under the microscope using vaginal material.

Dr. Ricardo Moro, BioCurex's CEO stated, "We are very satisfied with these findings which are in line with our previous results for detecting other types of cancers. The accumulation of positive results strongly suggests that RECAF is expressed by all types of cancer thus lending additional support to the idea of using this cancer marker for routine cancer screening. A RECAF test performed on blood collected for other routine clinical analysis would likely prove much cheaper than the traditional pap test, which currently involves a gynecologist to extract the sample as well as a pathologist (or a sophisticated artificial intelligence system) to read the results. Another very important application for Biocurex's blood test is to improve the follow-up screening of patients who have been operated on for cervical cancer; recurrence of the cancer or its metastases could be detected early by periodically monitoring the blood levels of RECAF, thereby significantly enhancing the chances of patient survival."

About cervical cancer:

Worldwide, cervical cancer claims around 190,000 lives annually, and is the third most common cause of cancer-related deaths. According to the American Cancer Society, the estimated number of women who will be diagnosed with invasive cervical cancer in 2005 is approximately 10,370 in the United States alone. About 3,710 women, the same source states, will die from cervical cancer.

About BioCurex:

BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapeutics. The technology identifies a cancer marker known as RECAF, which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells.

For more information, visit http://www.biocurex.co or call 604/207-9150.